Ryuto Nishisho1, Sentaro Kusuhara2, Noriyuki Sotani1, Kyong Woo Kim1, Atsuko Katsuyama-Yoshikawa1, Wataru Matsumiya1, Kengo Akashi3, Akio Morinobu3, Makoto Nakamura1. 1. Division of Ophthalmology, Department of Surgery, Kobe University Graduate School of Medicine, 7-5-2 Kusunoki-cho, Chuo-ku, Kobe, 650-0017, Japan. 2. Division of Ophthalmology, Department of Surgery, Kobe University Graduate School of Medicine, 7-5-2 Kusunoki-cho, Chuo-ku, Kobe, 650-0017, Japan. kusu@med.kobe-u.ac.jp. 3. Section of Rheumatology, Department of Internal Medicine, Kobe University Graduate School of Medicine, 7-5-2 Kusunoki-cho, Chuo-ku, Kobe, 650-0017, Japan.
Abstract
PURPOSE: To evaluate the short-term change in choroidal structure following adalimumab (ADA) treatment in refractory noninfectious uveitis. METHODS: This was a retrospective study of 33 eyes from 18 patients with refractory noninfectious uveitis. Subfoveal choroidal thickness (SFCT), the choroidal stromal index (CSI) defined as the proportion of stromal area to the total choroidal area were used as choroidal imaging parameters and were evaluated by enhanced depth imaging optical coherence tomography (EDI-OCT). The change in these parameters in the 2 months following initiation of ADA was analysed. A linear mixed-effect model was used to assess the effect of ADA treatment. RESULTS: The causes of uveitis were Vogt-Koyanagi-Harada disease (VKHD) (42.4%), presumed autoimmune retinopathy (15.2%), others (12.1%) and unclassified (30.3%). In the analysis of all eyes, the SFCT was 309.7 ± 113.1 μm at baseline, 295.7 ± 114.5 μm at 1 month and 275.2 ± 98.8 μm at 2 months after ADA initiation (P < 0.001). The CSI was 0.275 ± 0.050 at baseline, 0.273 ± 0.068 at 1 month and 0.273 ± 0.046 at 2 months (P = 0.785). In the subgroup analysis, the SFCT decreased significantly from baseline to 2 months in VKHD eyes (P = 0.007) and unclassified eyes (P = 0.034). There was no significant change in CSI in either subgroup. CONCLUSIONS: In the assessment of short-term response to ADA treatment in uveitic eyes, using EDI-OCT, the SFCT appears to be more effective as a choroidal imaging biomarker than the CSI, especially in VKHD eyes.
PURPOSE: To evaluate the short-term change in choroidal structure following adalimumab (ADA) treatment in refractory noninfectious uveitis. METHODS: This was a retrospective study of 33 eyes from 18 patients with refractory noninfectious uveitis. Subfoveal choroidal thickness (SFCT), the choroidal stromal index (CSI) defined as the proportion of stromal area to the total choroidal area were used as choroidal imaging parameters and were evaluated by enhanced depth imaging optical coherence tomography (EDI-OCT). The change in these parameters in the 2 months following initiation of ADA was analysed. A linear mixed-effect model was used to assess the effect of ADA treatment. RESULTS: The causes of uveitis were Vogt-Koyanagi-Harada disease (VKHD) (42.4%), presumed autoimmune retinopathy (15.2%), others (12.1%) and unclassified (30.3%). In the analysis of all eyes, the SFCT was 309.7 ± 113.1 μm at baseline, 295.7 ± 114.5 μm at 1 month and 275.2 ± 98.8 μm at 2 months after ADA initiation (P < 0.001). The CSI was 0.275 ± 0.050 at baseline, 0.273 ± 0.068 at 1 month and 0.273 ± 0.046 at 2 months (P = 0.785). In the subgroup analysis, the SFCT decreased significantly from baseline to 2 months in VKHD eyes (P = 0.007) and unclassified eyes (P = 0.034). There was no significant change in CSI in either subgroup. CONCLUSIONS: In the assessment of short-term response to ADA treatment in uveitic eyes, using EDI-OCT, the SFCT appears to be more effective as a choroidal imaging biomarker than the CSI, especially in VKHD eyes.
Authors: Eric B Suhler; Alfredo Adán; Antoine P Brézin; Eric Fortin; Hiroshi Goto; Glenn J Jaffe; Toshikatsu Kaburaki; Michal Kramer; Lyndell L Lim; Cristina Muccioli; Quan Dong Nguyen; Joachim Van Calster; Luca Cimino; Martina Kron; Alexandra P Song; Jianzhong Liu; Sophia Pathai; Anne Camez; Ariel Schlaen; Mirjam E J van Velthoven; Albert T Vitale; Manfred Zierhut; Samir Tari; Andrew D Dick Journal: Ophthalmology Date: 2018-02-09 Impact factor: 12.079
Authors: Glenn J Jaffe; Andrew D Dick; Antoine P Brézin; Quan Dong Nguyen; Jennifer E Thorne; Philippe Kestelyn; Talin Barisani-Asenbauer; Pablo Franco; Arnd Heiligenhaus; David Scales; David S Chu; Anne Camez; Nisha V Kwatra; Alexandra P Song; Martina Kron; Samir Tari; Eric B Suhler Journal: N Engl J Med Date: 2016-09-08 Impact factor: 91.245
Authors: Quan Dong Nguyen; Pauline T Merrill; Glenn J Jaffe; Andrew D Dick; Shree Kumar Kurup; John Sheppard; Ariel Schlaen; Carlos Pavesio; Luca Cimino; Joachim Van Calster; Anne A Camez; Nisha V Kwatra; Alexandra P Song; Martina Kron; Samir Tari; Antoine P Brézin Journal: Lancet Date: 2016-08-16 Impact factor: 79.321